Expert consensus on the combination of anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma (2025 edition)
Head and neck squamous cell carcinoma (HNSCC) is the most common type of head and neck cancer, and its treatment prognosis remains suboptimal. Although the survival of HNSCC patients has improved with the widespread use of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies and immune...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of China Oncology
2025-05-01
|
| Series: | Zhongguo aizheng zazhi |
| Subjects: | |
| Online Access: | https://www.china-oncology.com/fileup/1007-3639/PDF/1749540851103-2132024817.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|